These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 10418759)
1. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae. Kearney JA; Barbadora K; Mason EO; Wald ER; Green M Int J Antimicrob Agents; 1999 Jul; 12(2):141-4. PubMed ID: 10418759 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Patel R; Rouse MS; Piper KE; Steckelberg JM Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862 [TBL] [Abstract][Full Text] [Related]
3. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Mason EO; Lamberth LB; Kaplan SL Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Betriu C; Redondo M; Palau ML; Sánchez A; Gómez M; Culebras E; Boloix A; Picazo JJ Antimicrob Agents Chemother; 2000 Jul; 44(7):1838-41. PubMed ID: 10858339 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of linezolid in experimental otitis media. Pelton SI; Figueira M; Albut R; Stalker D Antimicrob Agents Chemother; 2000 Mar; 44(3):654-7. PubMed ID: 10681334 [TBL] [Abstract][Full Text] [Related]
6. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae. Baum SE; Crawford SA; McElmeel ML; Whitney CG; Jorgensen JH Antimicrob Agents Chemother; 2002 Sep; 46(9):3094-5. PubMed ID: 12183281 [TBL] [Abstract][Full Text] [Related]
7. [Antibiotic resistance analysis of Ge LL; Han ZY; Liu AH; Zhu L; Meng JH Zhonghua Er Ke Za Zhi; 2017 Feb; 55(2):109-114. PubMed ID: 28173648 [No Abstract] [Full Text] [Related]
8. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia. Gosbell IB; Fernandes LA; Fernandes CJ Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725 [TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963 [TBL] [Abstract][Full Text] [Related]
10. In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. Carsenti-Dellamonica H; Galimand M; Vandenbos F; Pradier C; Roger PM; Dunais B; Sabah M; Mancini G; Dellamonica P J Antimicrob Chemother; 2005 Oct; 56(4):633-42. PubMed ID: 16135525 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media. Humphrey WR; Shattuck MH; Zielinski RJ; Kuo MS; Biermacher JJ; Smith DP; Jensen JL; Schaadt RD; Zurenko GE; Richards IM Antimicrob Agents Chemother; 2003 Apr; 47(4):1355-63. PubMed ID: 12654670 [TBL] [Abstract][Full Text] [Related]
12. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes. Mason EO; Wald ER; Bradley JS; Barson WJ; Kaplan SL; Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838 [TBL] [Abstract][Full Text] [Related]
13. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Choi S; Im W; Bartizal K Antimicrob Agents Chemother; 2012 Sep; 56(9):4713-7. PubMed ID: 22713339 [TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Andes D; van Ogtrop ML; Peng J; Craig WA Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354 [TBL] [Abstract][Full Text] [Related]
15. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. Mazzariol A; Koncan R; Vitali LA; Cornaglia G J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of antibiotics commonly used in the treatment of otitis media against Streptococcus pneumoniae isolates with different susceptibilities to penicillin. Tarpay MM; Welch DF; Salari H; Marks MI Antimicrob Agents Chemother; 1982 Jul; 22(1):145-7. PubMed ID: 6922691 [TBL] [Abstract][Full Text] [Related]
17. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Wald ER; Mason EO; Bradley JS; Barson WJ; Kaplan SL; Pediatr Infect Dis J; 2001 Jan; 20(1):34-9. PubMed ID: 11176564 [TBL] [Abstract][Full Text] [Related]